Ewing Sarcoma Drug Pipeline Analysis Report 2025

Ewing sarcoma (ES) is a rare and aggressive cancer that primarily affects bones or soft tissue, commonly occurring in children and young adults. It affects approximately 2.1 per million children globally and is the second most prevalent bone sarcoma after osteosarcoma. There is a significant unmet clinical need for better therapies, as current treatment options, such as chemotherapy, surgery, and radiation, have limited long-term efficacy. The increasing focus on targeted therapies and novel Ewing sarcoma drug candidates is driving pipeline expansion.

Report Coverage

The Ewing Sarcoma Drug Pipeline Insight Report by the publisher gives comprehensive insights into Ewing sarcoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Ewing sarcoma. The Ewing sarcoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Ewing sarcoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Ewing sarcoma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Ewing sarcoma.

Ewing Sarcoma Drug Pipeline Outlook

Ewing Sarcoma is a rare and aggressive cancer that primarily affects bones or soft tissues in children and young adults. It occurs when abnormal cells appear in the bones or cartilage, often in the pelvis, thigh, or chest area. The exact cause is unknown, however, it involves genetic mutations, including a fusion of the EWSR1 gene with other genes.

Ewing Sarcoma treatment typically involves a combination of surgery, chemotherapy, and radiation therapy. Surgery aims to eliminate the tumor, while chemotherapy targets cancer cells throughout the body. Radiation may be utilized for tumors that cannot be surgically removed. Treatment plans can be customized based on the tumor's location and stage.

Ewing Sarcoma Epidemiology

Ewing sarcoma has an incidence of 2.1 cases per million children worldwide, making it the second most common bone sarcoma after osteosarcoma. In the United States, the estimated incidence is 2.9 cases per million children, accounting for 10%-15% of malignant bone tumors and 3% of all pediatric cancers. In the United Kingdom, approximately 90 new cases are diagnosed annually, while in India, Ewing sarcoma represents 3%-4% of cancers in children aged 0-14 years.

Ewing Sarcoma Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of Ewing sarcoma drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• CAR-T Cell Therapies
• Gene Therapies
• RNA-Based Therapies
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Ewing Sarcoma - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total Ewing sarcoma clinical trials.

Ewing Sarcoma - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the Ewing sarcoma pipeline analysis include small molecules, monoclonal antibodies, CAR-T cell therapies, gene therapies, RNA-based therapies, and others. The Ewing sarcoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Ewing sarcoma.

Ewing Sarcoma Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the Ewing sarcoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Ewing sarcoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Ewing sarcoma clinical trials:

• Eli Lilly and Company
• Pfizer
• Jazz Pharmaceuticals
• Shanghai Pharmaceuticals Holding Co., Ltd.
• Beijing Konruns Pharmaceutical Co., Ltd.
• Inhibrx Biosciences, Inc.
• Salarius Pharmaceuticals, LLC
• Iovance Biotherapeutics, Inc.
• Merck Sharp & Dohme LLC
• Fusion Pharmaceuticals Inc.
• Hoffmann-La Roche
• Ipsen

Ewing Sarcoma Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Ewing sarcoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Ewing sarcoma drug candidates.

Drug: Vincristine-Topotecan-Cyclophosphamide

Vincristine, topotecan, and cyclophosphamide are chemotherapy drugs that target rapidly dividing cancer cells, playing key roles in treating various cancers, including Ewing sarcoma. The Phase 3 clinical trial sponsored by the Children's Oncology Group is investigating how the combination of these three drugs, in addition to the standard chemotherapy regimen, affects event-free and overall survival in children and young adults with localized Ewing sarcoma.

Drug: Abemaciclib with Chemotherapy

Abemaciclib is a small molecule inhibitor targeting CDK4 and CDK6, which play a crucial role in regulating the cell cycle. A Phase 2 study, sponsored by Eli Lilly and Company, aims to assess the efficacy of adding Abemaciclib to chemotherapy for relapsed or refractory Ewing's sarcoma. This trial seeks to improve treatment outcomes in patients who have not responded to standard therapies.

Drug: Seclidemstat

Seclidemstat (SP-2577), is a novel, oral, reversible LSD1 inhibitor being investigated in a Phase 1 clinical trial sponsored by Salarius Pharmaceuticals. The objective of this study is to evaluate the safety and efficacy of Seclidemstat, both as a single agent and in combination with topotecan and cyclophosphamide, in patients with relapsed or refractory Ewing sarcoma and selected sarcomas. This drug offers the potential for treating sarcomas with limited therapeutic options.

Reasons To Buy This Report

The Ewing Sarcoma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Ewing sarcoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Ewing sarcoma collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Ewing Sarcoma - Pipeline Insight Report

• Which companies/institutions are leading the Ewing sarcoma drug development?
• What is the efficacy and safety profile of Ewing sarcoma pipeline drugs?
• Which company is leading the Ewing sarcoma pipeline development activities?
• What is the current Ewing sarcoma commercial assessment?
• What are the opportunities and challenges present in the Ewing sarcoma drug pipeline landscape?
• What is the efficacy and safety profile of Ewing sarcoma pipeline drugs?
• Which company is conducting major trials for Ewing sarcoma drugs?
• Which companies/institutions are involved in Ewing sarcoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Ewing sarcoma?

This product will be delivered within 3-5 business days.